More heart victims die when clot-buster drug is used before angioplasty

Currently it is fairly common practice to give heart attack patients a clot-busting drug a few hours before planned angioplasty.

But now a major study has found that the practice could be dangerous.

Doctors often give the clot-dissolver in the hope that it will make the artery-widening operation more successful.

The researchers found that more patients died in the month following the procedure if they were given the drug.

Their findings are expected to prompt many doctors around the world to stop using the strategy, at least for now.

Apparently there are two main options for treating heart attack victims, a clot dissolving drug or angioplasty; this is a procedure where doctors thread a wire through the blood vessels to get at the blood clot that caused the heart attack.

The wire mechanically breaks up the clot, then doctors inflate a balloon to squash plaque against the wall of the artery and implant a tiny mesh tube at the site of a blockage which permanently props the artery open.

Angioplasty is widely considered the more effective option, but only as long as it is done by experienced doctors in well-equipped hospitals.

However, as most community hospitals do not have such expertise, patients are either treated with a clot-busting drug or transferred to a nearby hospital that can perform the angioplasty within three hours.

It apparently is unclear whether angioplasty would work better if the clot was dissolved before the procedure.

In cases where angioplasty cannot be performed immediately but can be done some time between one and three hours after the heart attack, doctors have been giving the clot-buster to patients in this situation anyway, in the hope it might help.

In this latest study, led by Dr Frans Van de Werf of the Catholic University of Leuven in Belgium, the strategies were compared among 1,667 patients in hospitals.

Half were given the clot-buster while en route to angioplasty, while the other half were given a fake pill.

The researchers found that 6% of patients who got the drug, TNKase, died within 30 days of the angioplasty, compared with only 3.8% of those in the angioplasty alone group.

The study, which was supposed to enroll 4,000 patients, was stopped prematurely once the difference in death rates between the two groups became apparent.

The findings were presented at the annual conference of the European Society of Cardiology in Sweden.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Caffeine's anti-inflammatory effects may help protect blood vessels